1Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan
2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Copyright © 2020 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest: Naoki Hosoe conducted independent research supported by a funding contribution from Covidien. Naoki Hosoe received a research grant from Olympus. The other authors have no financial conflicts of interest.
Study | Number of analyzed patients | Use of purgative | Total liquid (L) | Use of prokinetics | Total colon observation (%) | Used type of CCE | Sensitivity (%) | Specificity (%) | Correlation |
---|---|---|---|---|---|---|---|---|---|
Sung et al. (2012) [9] | 96 | PEG, NaP | 4.0 | Metoclopramide | 83 | CCE-1 | 89 | 75 | N/A |
Meister et al. (2013) [10] | 13 | PEG-ASC | 4.7 | Domperidone | 77 | CCE-1 | N/A | N/A | N/A |
Ye et al. (2013) [11] | 25 | PEG, NaP | 3.8 | Itopride | 100 (using EGD) | CCE-1 | N/A | N/A | 0.751 (kappa) |
Hosoe et al. (2013) [12] | 29 | PEG | 2.0 | Mosapride, metoclopramide | 69 | CCE-2 | N/A | N/A | 0.797 (rho) |
Usui et al. (2014) [13] | 20 | PEG, magnesium citrate | 2.2 | Mosapride, metoclopramide | 85 | CCE-2 | N/A | N/A | N/A |
Shi et al. (2017) [16] | 108 | PEG, NaP | 4.0 | Metoclopramide | 72 | CCE-2 | 93 | 85 | 0.69 (ICC) |
Okabayashi et al. (2018) [20] | 33 | PEG-ASC, castor oil | 3.0 | Metoclopramide | 94 | CCE-2 | N/A | N/A | N/A |
Takano et al. (2018) [19] | 30 | PEG-ASC, magnesium citrate | 3.4 | Mosapride | 93 | CCE-2 | N/A | N/A | N/A |
CCE, colon capsule endoscopy; CCE-1, first-generation colon capsule endoscopy; CCE-2, second-generation colon capsule endoscopy; EGD, esophagogastroduodenoscopy; ICC, intraclass correlation coefficient; N/A, not assessed; NaP, sodium phosphate; PEG, polyethylene glycol; PEG-ASC, polyethylene glycol solution containing ascorbic acid.
Study | Number of analyzed patients | Use of purgative | Total liquid (L) | Use of prokinetics | Total colon observation (%) | Used type of CCE | Sensitivity (%) | Specificity (%) | Correlation |
---|---|---|---|---|---|---|---|---|---|
Sung et al. (2012) [9] | 96 | PEG, NaP | 4.0 | Metoclopramide | 83 | CCE-1 | 89 | 75 | N/A |
Meister et al. (2013) [10] | 13 | PEG-ASC | 4.7 | Domperidone | 77 | CCE-1 | N/A | N/A | N/A |
Ye et al. (2013) [11] | 25 | PEG, NaP | 3.8 | Itopride | 100 (using EGD) | CCE-1 | N/A | N/A | 0.751 (kappa) |
Hosoe et al. (2013) [12] | 29 | PEG | 2.0 | Mosapride, metoclopramide | 69 | CCE-2 | N/A | N/A | 0.797 (rho) |
Usui et al. (2014) [13] | 20 | PEG, magnesium citrate | 2.2 | Mosapride, metoclopramide | 85 | CCE-2 | N/A | N/A | N/A |
Shi et al. (2017) [16] | 108 | PEG, NaP | 4.0 | Metoclopramide | 72 | CCE-2 | 93 | 85 | 0.69 (ICC) |
Okabayashi et al. (2018) [20] | 33 | PEG-ASC, castor oil | 3.0 | Metoclopramide | 94 | CCE-2 | N/A | N/A | N/A |
Takano et al. (2018) [19] | 30 | PEG-ASC, magnesium citrate | 3.4 | Mosapride | 93 | CCE-2 | N/A | N/A | N/A |
CCE, colon capsule endoscopy; CCE-1, first-generation colon capsule endoscopy; CCE-2, second-generation colon capsule endoscopy; EGD, esophagogastroduodenoscopy; ICC, intraclass correlation coefficient; N/A, not assessed; NaP, sodium phosphate; PEG, polyethylene glycol; PEG-ASC, polyethylene glycol solution containing ascorbic acid.